化学性质
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 422.42 |
| Cas No. | 625115-55-1 |
| Formula | C20H19FN8O2 |
| Synonyms | BAY 63-2521; BAY 632521 |
| Solubility | insoluble in EtOH; insoluble in H2O; ≥16.95 mg/mL in DMSO |
| Chemical Name | methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-N-methylcarbamate |
| Canonical SMILES | CN(C1=C(N=C(N=C1N)C2=NN(C3=C2C=CC=N3)CC4=CC=CC=C4F)N)C(=O)OC |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
资料参考
Riociguat (BAY 63-2521; BAY 632521) is a novel drug that is currently in clinical development by Bayer. Riociguat (BAY 63-2521; BAY 632521) is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.
m.cnreagent.com